Floatz logo

Floxuridine

Adrenal Cortical Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Adrenal Cortical Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Dana-Farber Cancer Institute
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2CCC
Ipilimumab
Dana-Farber Cancer Institute
Phase 2CCC
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2CCC
mRNA-0523-L001
Shanghai Jiao Tong University School of Medicine
N/AD

Same molecule, other indications

Floxuridine is also rated in:

colon carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
rectal carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
colon adenocarcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →